Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR/101 in Chronic Hard-to-Heal Wounds
NCT02839226Phase 2Unknown
- Sponsor
- Arava Bio Tech
- Start
- Aug 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enzastaurin in Chronic wound, Arterial ulcers, diabetic foot ulcer (DFU) and 1 more (2 arms), sponsored by Arava Bio Tech. Primary endpoint: Formation of new granulation tissue according to a Granulation Score at 28 days. Status: unknown.
02
Drugs
enzastaurin
03
Conditions
Chronic woundArterial ulcersdiabetic foot ulcer (DFU)venous ulcers (VLU)
Beyond the preview
Go deeper on NCT02839226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839226.